JP6687548B2 - 変性された潜在関連蛋白質構成物 - Google Patents

変性された潜在関連蛋白質構成物 Download PDF

Info

Publication number
JP6687548B2
JP6687548B2 JP2016574456A JP2016574456A JP6687548B2 JP 6687548 B2 JP6687548 B2 JP 6687548B2 JP 2016574456 A JP2016574456 A JP 2016574456A JP 2016574456 A JP2016574456 A JP 2016574456A JP 6687548 B2 JP6687548 B2 JP 6687548B2
Authority
JP
Japan
Prior art keywords
nucleic acid
region
polypeptide
lap
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016574456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526625A5 (enExample
JP2017526625A (ja
Inventor
ユティ チャーナホブスキイ
ユティ チャーナホブスキイ
リサ ムレン
リサ ムレン
ギリアン アダムス
ギリアン アダムス
ディビッド ジェイムス ゴールド
ディビッド ジェイムス ゴールド
ハーゼーン ムハマド
ハーゼーン ムハマド
Original Assignee
スティールシックス セラピューティクス リミテッド
スティールシックス セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スティールシックス セラピューティクス リミテッド, スティールシックス セラピューティクス リミテッド filed Critical スティールシックス セラピューティクス リミテッド
Publication of JP2017526625A publication Critical patent/JP2017526625A/ja
Publication of JP2017526625A5 publication Critical patent/JP2017526625A5/ja
Application granted granted Critical
Publication of JP6687548B2 publication Critical patent/JP6687548B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016574456A 2014-06-27 2015-06-26 変性された潜在関連蛋白質構成物 Expired - Fee Related JP6687548B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1411506.7A GB201411506D0 (en) 2014-06-27 2014-06-27 Modified latency associated protein construct
GB1411506.7 2014-06-27
PCT/GB2015/051877 WO2015198072A1 (en) 2014-06-27 2015-06-26 Modified latency associated protein construct

Publications (3)

Publication Number Publication Date
JP2017526625A JP2017526625A (ja) 2017-09-14
JP2017526625A5 JP2017526625A5 (enExample) 2018-06-28
JP6687548B2 true JP6687548B2 (ja) 2020-04-22

Family

ID=51410274

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016574456A Expired - Fee Related JP6687548B2 (ja) 2014-06-27 2015-06-26 変性された潜在関連蛋白質構成物

Country Status (5)

Country Link
US (2) US10435451B2 (enExample)
EP (1) EP3160992B1 (enExample)
JP (1) JP6687548B2 (enExample)
GB (1) GB201411506D0 (enExample)
WO (1) WO2015198072A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004679D0 (en) 2020-03-31 2020-05-13 Stealthyx Therapeutics Ltd Modified latercy associated protein construct
BR112022020440A2 (pt) * 2020-04-10 2022-12-27 Cytomx Therapeutics Inc Construtos de citocinas ativáveis e composições e métodos relacionados
US20240391964A1 (en) * 2020-07-17 2024-11-28 The University Of Western Australia Compositions and methods for the treatment of cancer
EP4308594A2 (en) 2021-03-16 2024-01-24 CytomX Therapeutics, Inc. Masked activatable cytokine constructs and related compositions and methods
KR20250133922A (ko) * 2023-01-12 2025-09-09 리제너론 파아마슈티컬스, 인크. TGFβ의 표적화된 전달을 위한 조성물 및 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284763A (en) 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US6942853B2 (en) 2001-01-09 2005-09-13 Queen Mary And Westfield College Latent fusion protein
WO2002059317A2 (en) * 2001-01-24 2002-08-01 Zymogenetics, Inc. Cub domain protein zcub3 and materials and methods for making it
AU2006302587A1 (en) * 2005-10-04 2007-04-19 Greenville Hospital System Latent procytotoxins and uses thereof
GB0724556D0 (en) 2007-12-17 2008-01-30 Queen Mary & Westfield College LAtency associated protein construct with aggrecanase sensitive cleavage site
EP2377888A1 (en) * 2010-04-07 2011-10-19 Corimmun GmbH Fusion protein

Also Published As

Publication number Publication date
EP3160992B1 (en) 2019-07-24
EP3160992A1 (en) 2017-05-03
JP2017526625A (ja) 2017-09-14
US20200062814A1 (en) 2020-02-27
US20170129931A1 (en) 2017-05-11
US10435451B2 (en) 2019-10-08
GB201411506D0 (en) 2014-08-13
WO2015198072A1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
US20240368236A1 (en) Growth differentiation factor 15 (gdf-15) constructs
US20200062814A1 (en) Modified Latency Associated Protein Construct
JP4201253B2 (ja) 薬学的活性物質に潜在性を提供する方法
JP5372917B2 (ja) 最適化されたＴＡＣＩ−Ｆｃ融合タンパク質
WO2017025698A1 (en) Bispecific, cleavable antibodies
KR102910874B1 (ko) 구획, 특히 cns로의 국소 전달을 위한 fc 변형 생물학적 제제
US11530247B2 (en) Single-chain TNF receptor 2 agonist fusion proteins
AU2002219345A1 (en) Latency associated peptide for providing latency to pharmaceutically active proteins
EA037256B1 (ru) Химерный белок мочевого трипсинового ингибитора (мти), содержащий домен мти и fc-домен igg1
JP5683272B2 (ja) アグリカナーゼ感受性切断部位を有する潜在関連タンパク質構築物
WO2021063313A1 (zh) 改变效应功能的Fc变体及其融合蛋白
US20070015253A1 (en) Latent fusion protein
WO2021198324A1 (en) Modified latency associated protein construct
HK40092774A (zh) 使用激活素受体ii型变体的方法
ZA200305237B (en) Latency associated peptide for providing latency to pharmaceutically active proteins
HK1144663A1 (en) Multimeric constructs

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20170518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180515

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200309

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200402

R150 Certificate of patent or registration of utility model

Ref document number: 6687548

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees